Clinical Trials Directory

Trials / Completed

CompletedNCT04176224

Clinical Pharmacology Study of Oral Edaravone in Patients With Amyotrophic Lateral Sclerosis

Clinical Pharmacology Study of Oral Edaravone in Patients With Amyotrophic Lateral Sclerosis (ALS)

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
9 (actual)
Sponsor
Tanabe Pharma Corporation · Industry
Sex
All
Age
20 Years – 75 Years
Healthy volunteers
Not accepted

Summary

To evaluate the pharmacokinetics of single doses of edaravone oral suspension in Patients with Amyotrophic Lateral Sclerosis

Conditions

Interventions

TypeNameDescription
DRUGMT-1186Suspension

Timeline

Start date
2019-04-17
Primary completion
2019-09-04
Completion
2019-09-04
First posted
2019-11-25
Last updated
2026-01-07
Results posted
2024-01-24

Locations

1 site across 1 country: Japan

Source: ClinicalTrials.gov record NCT04176224. Inclusion in this directory is not an endorsement.

Clinical Pharmacology Study of Oral Edaravone in Patients With Amyotrophic Lateral Sclerosis (NCT04176224) · Clinical Trials Directory